Pharmaceutical R-D Investment and Medicine... in South America

Published 2026-10-07 · 24Peaks Research

Pharmaceutical R-D Investment and Medicine Access in South America

Pharmaceutical R&D investment in South America is small in absolute terms compared to North America, Europe, and parts of Asia, but it is a strategically important indicator of a region's capacity to develop and produce medicines locally. As of the latest available year, no South American country ranks among the top global spenders on pharmaceutical research and development, and most regional R&D activity is concentrated in Brazil, Argentina, and Chile. This indicator is best read alongside medicine access metrics, because high R&D spending does not automatically translate into broad population access to affordable treatments.

What This Indicator Measures

Pharmaceutical R&D investment typically measures the money spent on discovering, testing, and developing new drugs and biologics, including preclinical research, clinical trials, and regulatory submission. In international statistics, this is often captured as business enterprise expenditure on R&D (BERD) in the pharmaceutical and biotechnology sector, or as gross domestic expenditure on R&D (GERD) for health-related fields.

Related access metrics measure whether medicines actually reach patients. Common measures include the share of the population with access to essential medicines, out-of-pocket spending on pharmaceuticals as a share of total health expenditure, and the local production capacity for generic and biosimilar drugs.

Key methodological points:

• The UNESCO Institute for Statistics and the OECD Frascati Manual define R&D as creative work undertaken systematically to increase the stock of knowledge. This definition is widely used by the World Bank and IMF when reporting national R&D data.
• Pharmaceutical R&D is usually reported as a share of GDP or in current US dollars, which makes cross-country comparison sensitive to exchange rate movements in South America.
• Access indicators come from World Health Organization (WHO) tracking of essential medicines and from national health accounts, which follow the System of Health Accounts methodology.

Why It Matters for Investors and Policymakers

For investors, pharmaceutical R&D intensity signals where innovation capacity, skilled labor, and intellectual property frameworks are relatively strong. A rising trend can indicate a more attractive environment for biotech partnerships, clinical trials, and contract manufacturing.

For policymakers, the stakes are different. South America imports a large share of its finished pharmaceuticals, so domestic R&D and production capacity affect both health security and trade balances. During global supply disruptions, countries with weaker local production face higher prices and shortages.

The indicator also matters for fiscal planning. Public pharmaceutical R&D is often funded through national research councils and public health institutes, so it competes with other budget priorities. Private R&D depends on patent protection, pricing rules, and the size of the domestic market.

• Higher R&D spending generally correlates with more clinical trial activity and a stronger regulatory pipeline.
• Medicine access depends more on procurement, pricing policy, and generic competition than on R&D spending alone.
• Countries with strong public research institutes, such as Brazil's Fiocruz and Argentina's Instituto Butantan, can produce vaccines and biologics even with modest overall R&D budgets.

Recent Trends Across South America

Across South America, pharmaceutical R&D remains a small fraction of global spending. As of the latest available year, total regional R&D expenditure is estimated in the low tens of billions of US dollars, with Brazil accounting for the majority. Brazil's gross R&D expenditure has hovered around 1.1 to 1.3 percent of GDP in recent years, but most of that is not pharmaceutical-specific. Argentina and Chile generally report national R&D spending below 1 percent of GDP, with health and pharmaceutical research forming only part of that total.

Several regional trends are visible:

• Brazil has expanded public funding for vaccines, biologics, and generics through its national health system and public laboratories.
• Argentina has maintained strong public research capacity through CONICET and public universities, though economic volatility creates funding uncertainty.
• Chile has attracted more clinical research and contract research activity, supported by stable regulation and trade openness.
• Colombia and Peru have smaller R&D bases but are increasing participation in regional clinical trials and public health research.

On the access side, most South American countries report relatively high availability of essential medicines in the public sector, but out-of-pocket spending remains significant. In several countries, households pay a substantial share of medicine costs directly, which limits effective access even when products are available in the market.

Comparison Examples

The table below compares illustrative values for four South American countries. Because exact pharmaceutical-specific R&D figures are not reported consistently across all countries, the recent value column uses national R&D intensity as a proxy, expressed as a share of GDP, as of the latest available year. 24Peaks hosts the latest series for each country.

These figures should be read with caution. National R&D totals include agriculture, energy, and other sectors, so the pharmaceutical share is smaller than the headline number. Countries that report higher R&D intensity are not necessarily better at delivering affordable medicines.

Limitations and Data Caveats

This indicator has several important limitations for analysts.

• Definitional inconsistency: Countries classify pharmaceutical R&D differently, and some include biotechnology, medical devices, or traditional medicine research under the same heading.
• Currency and inflation effects: South American currencies have experienced sharp swings, so US-dollar comparisons can distort real trends.
• Public versus private reporting: Private company R&D data is often incomplete, especially for smaller domestic firms that do not publish financial statements.
• Access measurement gaps: Essential medicine availability surveys are conducted periodically, not annually, so access data can lag R&D data by several years.
• Proxy problem: When pharmaceutical-specific R&D is unavailable, analysts use national R&D intensity as a proxy, which can overstate the sector's actual research effort.

Because of these gaps, investors should treat any single number as indicative rather than definitive and combine it with trade data, patent filings, and clinical trial registrations.

FAQ

What is pharmaceutical R&D investment and why does it matter in South America?

It measures spending on discovering and developing new medicines. In South America, it matters because it indicates how much the region can produce and innovate locally rather than relying on imports.

Which South American country spends the most on pharmaceutical R&D?

Brazil has the largest research base in the region, with the highest national R&D spending and the most developed public vaccine and biologics production. Argentina and Chile follow, though at lower absolute levels.

Does higher R&D spending mean better medicine access?

Not necessarily. Access depends on procurement, pricing, generic competition, and public health coverage. A country can have modest R&D spending but strong access through generics and public programs.

Why is pharmaceutical R&D data hard to compare across countries?

Definitions, currency effects, and incomplete private-sector reporting vary widely. Pharmaceutical-specific figures are often unavailable, so analysts use national R&D intensity as a proxy.

What is the outlook for pharmaceutical R&D in South America?

As of the latest available year, regional R&D is growing slowly, led by Brazil and supported by public institutes. Growth depends on macroeconomic stability, public funding, and regulatory predictability.

Compare This Indicator on 24Peaks

To explore the latest available R&D and medicine access data for South American countries, compare the indicator directly on the 24Peaks workbench.